Ordering Recommendation

HIV genotyping provides susceptibility information for integrase inhibitors (INI). Intended for patients with viral load >500 copies/mL.

Mnemonic
HIV1INT
Methodology

Reverse Transcription Polymerase Chain Reaction/Sequencing

Performed

Tue, Fri

Reported

7-10 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.

Specimen Preparation

Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5  mL)

Storage/Transport Temperature

Frozen.

Unacceptable Conditions

Serum. Heparinized specimens.

Remarks

Please submit most recent viral load and test date, if available.

Stability

On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months

Reference Interval

By report

Interpretive Data

The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.

Hotline History
N/A
Components
Component Test Code* Component Chart Name LOINC
2004458 HIV-1 Integrase Inhib. Resistance, Seq 72560-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • HIV Drug Resistance
  • HIV Integrase Genotype
  • HIV Integrase Inhibitor Resistance
  • HIV Treatment Susceptibility Testing
  • HIV1 Integrase Resistance
  • HIV1 Integrase Sequencing
  • HIV1 Sequencing
  • Raltegravir (Isentress(TM)) Resistance
HIV-1 Integrase Inhibitor Resistance by Sequencing